| Identification | |
| Name: | Tofisopam |
| Synonyms: | 1-(3,4-Dimethoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine;7,8-Dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5H-2,3-benzodiazepine;EGYT 341;Grandaxin;Seriel; |
| CAS: | 22345-47-7 |
| EINECS: | 244-922-3 |
| Molecular Formula: | C22H26N2O4 |
| Molecular Weight: | 382.50 |
| InChI: | InChI=1/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3 |
| Molecular Structure: |  |
| Properties | |
| Transport: | UN 3077 |
| Density: | 1.15g/cm3 |
| Refractive index: | 1.558 |
| Water Solubility: | DMSO: ~14 mg/mL |
| Solubility: | DMSO: ~14 mg/mL |
| Appearance: | white solid |
| Specification: |
Tofisopam ,its cas register number is 22345-47-7. It also can be called Grandaxin ; Dextofisopam ; 7,8-Dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5H-2,3-benzodiazepine and tofizopam . It is not reported as causing dependence to the same extent as other benzodiazepines, but is still recommended to be prescribed for a maximum of 12 weeks. Tofisopam (CAS NO.22345-47-7) is claimed to be a PDE10A inhibitor ,and so it may provide an alternative mechanism of action for its various therapeutic effects. This action is proposed to make tofisopam potentially useful as a treatment for schizophrenia. |
| Packinggroup: | III |
| Color: | white |
| Safety Data | |
| Hazard Symbols |
Xn: Harmful
N: Dangerous for the environment
|
 |
|
